|Calculated MW||This protein is fused with 6×His tag at the C-terminus, has a calculated MW of 52.9 kDa. The predicted N-terminus is Ala 22. DTT-reduced Protein migrates as 85-100 kDa due to glycosylation.|
|Other Names||GPNMB, HGFIN, NMB, Osteoactivin|
|Results||ED50 for this effect is typically 4 - 16 µg/ml|
|Target/Specificity||Osteoactivin / GPNMB|
|Application Notes||Centrifuge the vial prior to opening. Reconstitute in PBS, pH 7.4. Do not vortex.|
|Storage||-20°C; Lyophilized from 0.22 µm filtered solution in PBS, pH 7.5. Normally Mannitol or Trehalose are added as protectants before lyophilization.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Transmembrane glycoprotein NMB (GPNMB) is also known as Transmembrane glycoprotein HGFIN, DC-HIL and Osteoactivin (OA), which belongs to the PMEL/NMB family. GPNMB contains one PKD domain. GPNMB is a transmembrane glycoprotein that is up-regulated in various cancer cells, including in glioblastoma multiforme and is expressed in many melanoma cells, as well as in tissue macrophages. GPNMB protein acts as a downstream mediator of BMP-2 effects on osteoblast differentiation and function. GPNMB participates in bone mineralization, and functions as a negative regulator of inflammation in macrophages.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.